Why is Sotac Pharma. falling/rising?

As of 20-Jun, Sotac Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 108.40, which reflects a decrease of 4.45 or 3.94%. The stock has underperformed its sector today by 4.55%, and it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 80% compared to the 5-day average. Over the past year, the stock has generated a return of -8.14%, while its profits have increased by 79%, indicating a disconnect between performance and stock price. However, the company has not declared results in the last six months, which raises concerns about its long-term fundamental strength. In the broader market context, the stock's performance has been notably weaker compared to the benchmark, with a 1-week return of -13.28% against the Sensex's gain of 1.59%. This trend of consistent underperformance has been evident over the last three years, where the stock has lagged behind the BSE 500 in each annual period. Despite having an attractive valuation with a low PEG ratio of 0.3, the company's high Debt to EBITDA ratio of 2.52 times and slow net sales growth of 11.90% over the last five years contribute to a negative outlook, further exacerbating the stock's decline.